Meeting
2016 ASCO Annual Meeting
Phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer.
Authors
Makoto Ueno
Division of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Japan
Makoto Ueno , Masato Ozaka , Hiroshi Ishii , Tosiya Sato , Masafumi Ikeda , Kazuhiro Uesugi , Naohiro Sata , Kouichirou Miyashita , Nobumasa Mizuno , Kunihiro Tsuji , Takuji Okusaka , Junji Furuse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
UMIN000013301
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4111)
DOI
10.1200/JCO.2016.34.15_suppl.4111
Abstract #
4111
Poster Bd #
103
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.
First Author: Makoto Ueno
Poster
2020 ASCO Virtual Scientific Program
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.
First Author: Shintaro Nakano
Poster
2015 Gastrointestinal Cancers Symposium
Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC).
First Author: Edward Samuel James
Poster
2014 Gastrointestinal Cancers Symposium
Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).
First Author: Edward Samuel James